Effect of Long‐Term Voclosporin Treatment on Renal Histology in Patients With Active Lupus Nephritis With Repeat Renal Biopsies
Outcomes from this small subgroup show that exposure to study treatment was not associated with nephrotoxicity based on histopathologic evaluation after 18 months. These data are reassuring and further contribute to the safety profile of voclosporin for the treatment of adults with active LN.
Authors
- Amit Saxena (ORCID: https://orcid.org/0000-0003-0098-1083)
- Robert B. Huizinga (ORCID: https://orcid.org/0000-0001-8703-7655)
- Brad H. Rovin (ORCID: https://orcid.org/0000-0001-5639-0210)
- Samir V. Parikh (ORCID: https://orcid.org/0000-0001-7023-525X)
- Clarissa A. Cassol (ORCID: https://orcid.org/0000-0001-7536-6806)
- Ernie Yap (ORCID: https://orcid.org/0000-0002-2799-2367)
- Clint W. Abner
- David R.W. Jayne (ORCID: https://orcid.org/0000-0002-1712-0637)
- Vanessa Birardi (ORCID: https://orcid.org/0000-0002-5429-7546)
- Neil Solomons
Institutions
- Novartis (Switzerland) (CH)
- University of Cambridge (GB)
- The Ohio State University Wexner Medical Center (US)
- Arkana Laboratories (US)
- Cambridge School (PT)
- Novartis (United States) (US)
- Lions Gate Hospital (CA)
- Aurinia (Canada) (CA)
- Biological Consulting Services (United States) (US)
- New York University (US)
Publication Details
- Journal
- Arthritis & Rheumatology
- Published
- 2025-05-02
- DOI
- https://doi.org/10.1002/art.43209
- Citations
- 4
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 6.67
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- GlaxoSmithKline
- Alexion Pharmaceuticals
- EMD Serono
- National Institute of Diabetes and Digestive and Kidney Diseases